Efficient elimination of primary B-ALL cells in vitro and in vivo using a novel 4-1BB-based CAR targeting a membrane-distal CD22 epitope

BACKGROUND: There are few therapeutic options available for patients with B-cell acute lymphoblastic leukemia (B-ALL) relapsing as CD19(–) either after chemotherapy or CD19-targeted immunotherapies. CD22-chimeric antigen receptor (CAR) T cells represent an attractive addition to CD19-CAR T cell ther...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Velasco-Hernandez, Talia, Zanetti, Samanta Romina, Roca-Ho, Heleia, Gutierrez-Aguera, Francisco, Petazzi, Paolo, Sánchez-Martínez, Diego, Molina, Oscar, Baroni, Matteo Libero, Fuster, Jose Luis, Ballerini, Paola, Bueno, Clara, Fernandez-Fuentes, Narcis, Engel, Pablo, Menendez, Pablo
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2020
Assuntos:
Immune Cell Therapies and Immune Cell Engineering
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7422657/
https://ncbi.nlm.nih.gov/pubmed/32788237
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-000896
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados